Krystexxa
·
- Prescription status not stated
- Muscles, joints and bones
- Active substance
- Pegloticase
- Used in
- Muscles, joints and bones
- Made by
- Crealta Pharmaceuticals Ireland Limited
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Krystexxa is indicated for the treatment of severe debilitating chronic tophaceous gout in adult patients who may also have erosive joint involvement and who have failed to normalize serum uric acid with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these medicines are contraindicated.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | Crealta Pharmaceuticals Ireland Limited |
|---|---|
| Active substance | Pegloticase |
| Used in | Muscles, joints and bones |
| Classification | M04AX02 · Muscles, joints and bones |
| Authorised on | 2013-01-08 |
| Last updated by the regulator | 2016-07-22 |
| EMA product number | EMEA/H/C/002208 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).